Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3428) 3428
Publication (210) 210
Newsletter (118) 118
Book Review (55) 55
Newspaper Article (25) 25
Conference Proceeding (16) 16
Magazine Article (16) 16
Book Chapter (11) 11
Dissertation (9) 9
Trade Publication Article (5) 5
Book / eBook (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
formoterol (2135) 2135
humans (2116) 2116
formoterol fumarate (1464) 1464
asthma (1418) 1418
male (1265) 1265
respiratory system (1153) 1153
female (1144) 1144
index medicus (1142) 1142
asthma - drug therapy (1085) 1085
administration, inhalation (980) 980
salmeterol (975) 975
middle aged (903) 903
adult (883) 883
bronchodilator agents - administration & dosage (807) 807
ethanolamines - administration & dosage (800) 800
budesonide (733) 733
bronchodilator agents - therapeutic use (660) 660
ethanolamines - therapeutic use (644) 644
aged (637) 637
pulmonary disease, chronic obstructive - drug therapy (632) 632
treatment outcome (610) 610
double-blind method (591) 591
pharmacology & pharmacy (583) 583
drug therapy, combination (541) 541
copd (491) 491
drug combinations (480) 480
albuterol - analogs & derivatives (470) 470
drug therapy (466) 466
salmeterol xinafoate (432) 432
adolescent (418) 418
obstructive pulmonary-disease (402) 402
salbutamol (400) 400
budesonide - administration & dosage (381) 381
efficacy (377) 377
lung diseases, obstructive (373) 373
chronic obstructive pulmonary disease (371) 371
adrenergic beta-agonists - therapeutic use (364) 364
albuterol - therapeutic use (363) 363
exacerbations (351) 351
ethanolamines - pharmacology (334) 334
asthma - physiopathology (327) 327
albuterol - administration & dosage (325) 325
bronchodilator agents - adverse effects (317) 317
corticosteroids (316) 316
fluticasone (313) 313
adrenergic beta-agonists - administration & dosage (312) 312
dose-response relationship, drug (310) 310
medicine, general & internal (300) 300
ethanolamines - adverse effects (296) 296
safety (294) 294
child (291) 291
pulmonary disease, chronic obstructive - physiopathology (289) 289
cross-over studies (288) 288
allergy (287) 287
tiotropium (286) 286
budesonide/formoterol (285) 285
inhaled corticosteroids (282) 282
time factors (282) 282
budesonide - therapeutic use (273) 273
animals (270) 270
nebulizers and vaporizers (266) 266
forced expiratory volume - drug effects (263) 263
anti-asthmatic agents - administration & dosage (259) 259
forced expiratory volume (255) 255
fluticasone propionate (248) 248
dosage and administration (247) 247
therapy (244) 244
double-blind (241) 241
adrenal cortex hormones - administration & dosage (240) 240
care and treatment (235) 235
anti-asthmatic agents - therapeutic use (231) 231
immunology (228) 228
research (226) 226
cardiac & cardiovascular systems (225) 225
pulmonary and respiratory medicine (219) 219
respiratory tract diseases (216) 216
adrenergic beta-2 receptor agonists - administration & dosage (214) 214
quality of life (210) 210
pulmonary/respiratory (207) 207
randomized controlled trials as topic (207) 207
adrenergic beta-agonists - pharmacology (206) 206
drug administration schedule (203) 203
combination (200) 200
bronchodilator agents - pharmacology (197) 197
analysis (193) 193
clinical trials (189) 189
single inhaler (189) 189
adrenal cortex hormones - therapeutic use (188) 188
metered dose inhalers (185) 185
albuterol (184) 184
severity of illness index (182) 182
respiratory function tests (180) 180
management (171) 171
aged, 80 and over (170) 170
children (169) 169
steroids (169) 169
young adult (164) 164
adrenergic beta-agonists - adverse effects (161) 161
antiasthmatic agents (161) 161
combination therapy (161) 161
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3374) 3374
German (83) 83
Spanish (38) 38
French (29) 29
Japanese (20) 20
Russian (17) 17
Polish (14) 14
Portuguese (10) 10
Chinese (9) 9
Italian (9) 9
Czech (7) 7
Danish (5) 5
Turkish (4) 4
Romanian (2) 2
Hungarian (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Inhaled Combined Budesonide–Formoterol as Needed in Mild Asthma
by O’Byrne, Paul M and FitzGerald, J. Mark and Bateman, Eric D and Barnes, Peter J and Zhong, Nanshan and Keen, Christina and Jorup, Carin and Lamarca, Rosa and Ivanov, Stefan and Reddel, Helen K
The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 20, pp. 1865 - 1876
In patients with mild asthma, inhaled glucocorticoid and β-agonist in a single inhaler, used as needed, was compared with maintenance glucocorticoid or... 
MAINTENANCE | MEDICINE, GENERAL & INTERNAL | CLINICAL-TRIAL | DOUBLE-BLIND | EXACERBATIONS | RELIEVER THERAPY | RANDOMIZED CONTROLLED-TRIAL | BUDESONIDE/FORMOTEROL | CORTICOSTEROIDS | COMBINATION | SINGLE INHALER | Terbutaline - adverse effects | Glucocorticoids - administration & dosage | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Male | Forced Expiratory Volume | Young Adult | Terbutaline - administration & dosage | Adult | Female | Surveys and Questionnaires | Maintenance Chemotherapy | Bronchodilator Agents - adverse effects | Child | Double-Blind Method | Drug Administration Schedule | Formoterol Fumarate - adverse effects | Administration, Inhalation | Asthma - drug therapy | Medication Adherence | Budesonide - adverse effects | Adolescent | Aged | Budesonide - administration & dosage | Drug Combinations | Formoterol Fumarate - administration & dosage | Diaries | Budesonide | Glucocorticoids | Research & development--R&D | Data processing | Inflammation | Patients | Asthma | Medicine | Terbutaline | Airway management | Formoterol | Clinical medicine | Drug dosages
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: Results of a 6-month randomized clinical trial
by Tashkin, Donald P and Rennard, Stephen I and Martin, Paula and Ramachandran, Sulabha and Martin, Ubaldo J and Silkoff, Philip E and Goldman, Mitchell
Drugs, ISSN 0012-6667, 2008, Volume 68, Issue 14, pp. 1975 - 2000
Background: The combination of an inhaled corticosteroid (ICS) and a long-acting bronchodilator is recommended in the treatment of patients with chronic... 
Chronic obstructive pulmonary disease, treatment | Budesonide, therapeutic use | Budesonide/formoterol, therapeutic use | Formoterol, therapeutic use | SURVIVAL | MORTALITY | FLUTICASONE PROPIONATE | SALMETEROL/FLUTICASONE PROPIONATE | EXACERBATIONS | PHARMACOLOGY & PHARMACY | TOXICOLOGY | FLOW LIMITATION | CORTICOSTEROIDS | IPRATROPIUM BROMIDE | COPD PATIENTS | SALMETEROL XINAFOATE | Bronchodilator Agents - therapeutic use | Dyspnea - chemically induced | Ethanolamines - adverse effects | Formoterol Fumarate | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Male | Ethanolamines - administration & dosage | Forced Expiratory Volume | Anti-Inflammatory Agents - adverse effects | Aged, 80 and over | Anti-Inflammatory Agents - therapeutic use | Metered Dose Inhalers | Adult | Anti-Inflammatory Agents - administration & dosage | Female | Bronchodilator Agents - adverse effects | Double-Blind Method | Aerosol Propellants | Budesonide - adverse effects | Budesonide - therapeutic use | Quality of Life | Ethanolamines - therapeutic use | Aged | Budesonide - administration & dosage | Respiratory Function Tests | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy
Journal Article
Details down arrow
3. ANÁLISIS DE COSTO EFECTIVIDAD DEL USO DE BUDESONIDA/FORMOTEROL FRENTE A SALMETEROL/FLUTICASONA, EN PACIENTES CON ASMA MODERADA Y SEVERA EN COLOMBIA
by ME Romero Prada and NC Roa Cardenas and LM Huerfano
Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research, ISSN 1098-3015, 10/2017, Volume 20, Issue 9, p. A889
Salmeterol | Formoterol
Journal Article
Details down arrow
4. Full Text RELIEVER THERAPY USING INHALED CORTICOSTEROID AND FORMOTEROL VERSUS SHORT ACTING BETA2 AGONIST IN CHRONIC ASTHMATIC PATIENTS: A META‐ANALYSIS
Respirology, ISSN 1323-7799, 11/2019, Volume 24, Issue S2, pp. 197 - 197
Formoterol | Asthma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text ADVERSE EVENTS OF AS‐NEEDED INHALED CORTICOSTEROID AND FORMOTEROL VERSUS SHORT ACTING BETA2 AGONISTS IN ASTHMA EXACERBATIONS: A META‐ANALYSIS
Respirology, ISSN 1323-7799, 11/2019, Volume 24, Issue S2, pp. 199 - 200
Formoterol | Asthma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text IS INHALED STEROID‐FORMOTEROL ESSENTIAL FOR SUCCESS IN ASTHMA ACTION PLANS?
Respirology, ISSN 1323-7799, 11/2019, Volume 24, Issue S2, pp. 63 - 63
Formoterol | Asthma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text APPLICATION OF EXTRAFINE BECLOMETHASONE/FORMOTEROL TO ACHIEVE ASTHMA CONTROL IN PATIENTS WITH COLD AND/OR OSMOTIC AIRWAY HYPERRESPONSIVENESS
Respirology, ISSN 1323-7799, 11/2019, Volume 24, Issue S2, pp. 196 - 196
Formoterol | Asthma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Asthma paradoxes: time for a new approach across the spectrum of asthma severity
by Beasley, R and Bird, G and Harper, J and Weatherall, M
EUROPEAN RESPIRATORY JOURNAL, ISSN 0903-1936, 04/2019, Volume 53, Issue 4
RESPIRATORY SYSTEM | BUDESONIDE-FORMOTEROL
Journal Article
Details down arrow
9. Full Text As-Needed Budesonide–Formoterol versus Maintenance Budesonide in Mild Asthma
by Bateman, Eric D and Reddel, Helen K and O’Byrne, Paul M and Barnes, Peter J and Zhong, Nanshan and Keen, Christina and Jorup, Carin and Lamarca, Rosa and Siwek-Posluszna, Agnieszka and FitzGerald, J. Mark
The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 20, pp. 1877 - 1887
Inhaled glucocorticoid plus β-agonist in a single inhaler was compared with maintenance inhaled glucocorticoid for exacerbation risk among patients with mild... 
BETA-AGONIST | MEDICINE, GENERAL & INTERNAL | RESCUE TREATMENT | TERM CLINICAL-TRIAL | INHALED CORTICOSTEROIDS | DOUBLE-BLIND | EXACERBATIONS | PERSISTENT ASTHMA | RELIEVER THERAPY | RANDOMIZED CONTROLLED-TRIAL | ADHERENCE | Terbutaline - adverse effects | Glucocorticoids - administration & dosage | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Male | Forced Expiratory Volume | Young Adult | Terbutaline - administration & dosage | Aged, 80 and over | Adult | Female | Surveys and Questionnaires | Maintenance Chemotherapy | Bronchodilator Agents - adverse effects | Child | Severity of Illness Index | Double-Blind Method | Drug Administration Schedule | Formoterol Fumarate - adverse effects | Proportional Hazards Models | Administration, Inhalation | Asthma - drug therapy | Medication Adherence | Budesonide - adverse effects | Adolescent | Aged | Budesonide - administration & dosage | Drug Combinations | Formoterol Fumarate - administration & dosage | Terbutaline | Budesonide | Glucocorticoids | Research & development--R&D | Formoterol | Patients | Drug dosages | Asthma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Efficacy and Tolerability of Budesonide/Formoterol Added to Tiotropium in Patients with Chronic Obstructive Pulmonary Disease
by Welte, Tobias and Miravitlles, Marc and Hernandez, Paul and Eriksson, Goran and Peterson, Stefan and Polanowski, Tomasz and Kessler, Romain and Respiratory Medicine and Allergology and Lund University and Lunds universitet and Lungmedicin och Allergologi, Lund
American Journal of Respiratory and Critical Care Medicine, ISSN 1073-449X, 10/2009, Volume 180, Issue 8, pp. 741 - 750
Rationale: Budesonide/formoterol and tiotropium are commonly used maintenance treatments for patients with chronic obstructive pulmonary disease. Combining... 
Tiotropium | Exacerbations | Budesonide/formoterol | Morning activities | Morning symptoms | morning symptoms | HYPERINFLATION | SALMETEROL/FLUTICASONE PROPIONATE | BUDESONIDE | tiotropium | SALMETEROL | FORMOTEROL | METERED-DOSE INHALER | FLUTICASONE PROPIONATE | RESPIRATORY SYSTEM | exacerbations | morning activities | COPD PATIENTS | budesonide/formoterol | AIR-FLOW OBSTRUCTION | CRITICAL CARE MEDICINE | Ethanolamines - adverse effects | Formoterol Fumarate | Humans | Middle Aged | Male | Muscarinic Antagonists - therapeutic use | Ethanolamines - administration & dosage | Forced Expiratory Volume | Adrenergic beta-Agonists - administration & dosage | Aged, 80 and over | Adult | Female | Drug Therapy, Combination | Scopolamine Derivatives - therapeutic use | Adrenergic beta-Agonists - adverse effects | Tiotropium Bromide | Double-Blind Method | Administration, Inhalation | Adrenal Cortex Hormones - adverse effects | Budesonide - adverse effects | Quality of Life | Aged | Budesonide - administration & dosage | Adrenal Cortex Hormones - administration & dosage | Pulmonary Disease, Chronic Obstructive - drug therapy | Index Medicus | Abridged Index Medicus | Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Lungmedicin och allergi | Klinisk medicin | Respiratory Medicine and Allergy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax (R) compared with budesonide/formoterol Turbuhaler (R) in adult patients with asthma: the Easy Low Instruction Over Time (ELIOT) study
by Price, D.B and Thomas, Vicky and Dekhuijzen, P.N.R and Bosnic-Anticevich, S and Roches, Nicolas and Lavorini, F and Canvin, Janice and Chrystyn, H
BMC Pulmonary Medicine, ISSN 1471-2466, 2018, Volume 18, Issue 1, pp. 107 - 14
Background: Incorrect inhaler technique is a common cause of poor asthma control. This two-phase pragmatic study evaluated inhaler technique mastery and... 
Pragmatic clinical trial | Inhaler mastery | Dry-powder inhaler | Intuitive | Budesonide/formoterol | Inhaler technique | Asthma | DRY POWDER INHALERS | ERRORS | MANAGEMENT | MEDICAL PERSONNELS KNOWLEDGE | PROFESSIONALS | METERED-DOSE INHALER | PRIMARY-CARE | REAL-LIFE | RESPIRATORY SYSTEM | DEVICES | COPD | Bronchodilator Agents - therapeutic use | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Male | Adrenal Cortex Hormones - therapeutic use | Adrenergic beta-2 Receptor Agonists - therapeutic use | Adult | Female | Dry Powder Inhalers - methods | Formoterol Fumarate - therapeutic use | Asthma - physiopathology | Cross-Sectional Studies | Administration, Inhalation | Logistic Models | Treatment Outcome | United Kingdom | Asthma - drug therapy | Budesonide, Formoterol Fumarate Drug Combination - therapeutic use | Budesonide - therapeutic use | Adrenergic beta-2 Receptor Agonists - administration & dosage | Aged | Budesonide - administration & dosage | Budesonide, Formoterol Fumarate Drug Combination - administration & dosage | Adrenal Cortex Hormones - administration & dosage | Formoterol Fumarate - administration & dosage | Budesonide | Control | Usage | Formoterol | Dosage and administration | Drug therapy | Comparative analysis | Inhalers
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Long term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease
by Hanania, Nicola A and Tashkin, Donald P and Kerwin, Edward M and Donohue, James F and Denenberg, Michael and O'Donnell, Denis E and Quinn, Dean and Siddiqui, Shahid and Orevillo, Chad and Maes, Andrea and Reisner, Colin
Respiratory Medicine, ISSN 0954-6111, 2017, Volume 126, pp. 105 - 115
Abstract Background The long-term safety and efficacy of a novel Co-Suspension™ Delivery Technology glycopyrrolate (GP)/formoterol fumarate (FF) 18/9.6 μg... 
Pulmonary/Respiratory | Muscarinic antagonists | Co-Suspension™ Delivery Technology | Metered dose inhaler | β2-agonist | COPD | agonist | INDACATEROL | TWICE-DAILY FORMOTEROL | PLACEBO | CARDIAC & CARDIOVASCULAR SYSTEMS | QVA149 | COMBINATION | ONCE-DAILY TIOTROPIUM | Co-Suspension (TM) Delivery Technology | THERAPY | RESPIRATORY SYSTEM | GLYCOPYRRONIUM | beta-agonist | COPD PATIENTS | Bronchodilator Agents - therapeutic use | Bronchodilator Agents - administration & dosage | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Male | Muscarinic Antagonists - therapeutic use | Tiotropium Bromide - administration & dosage | Metered Dose Inhalers - utilization | Adrenergic beta-2 Receptor Agonists - therapeutic use | Female | Drug Therapy, Combination | Glycopyrrolate - adverse effects | Severity of Illness Index | Formoterol Fumarate - pharmacology | Drug Tolerance | Formoterol Fumarate - adverse effects | Administration, Inhalation | Treatment Outcome | Tiotropium Bromide - pharmacology | Muscarinic Antagonists - administration & dosage | Glycopyrrolate - administration & dosage | Smoking - epidemiology | Adrenergic beta-2 Receptor Agonists - administration & dosage | Dyspnea - drug therapy | Glycopyrrolate - pharmacology | Aged | Formoterol Fumarate - administration & dosage | Pulmonary Disease, Chronic Obstructive - drug therapy | Medicine, Experimental | Medical research | Medical colleges | Formoterol | Lung diseases, Obstructive | Care and treatment | Respiratory therapy | Drugs | Drug delivery systems | Effectiveness | Statistical analysis | Lung diseases | Clinical trials | Glycopyrrolate | Long term | Side effects | Randomization | Dyspnea | Technology | Obstructive lung disease | Chronic obstructive pulmonary disease | Safety | Drug therapy | Respiration
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Budesonide + formoterol delivered via Spiromax® for the management of asthma and COPD: The potential impact on unscheduled healthcare costs of improving inhalation technique compared with Turbuhaler
by Lewis, A and Torvinen, S and Dekhuijzen, P.N.R and Chrystyn, H and Melani, A and Zöllner, Y and Kolbe, K and Watson, A.T and Blackney, M and Plich, A
Respiratory Medicine, ISSN 0954-6111, 08/2017, Volume 129, pp. 179 - 188
Fixed-dose combinations of inhaled corticosteroids and long-acting β agonists are commonly used for the treatment of asthma and COPD. However, the most... 
Spiromax | Budget impact | Inhalation technique | Asthma | COPD | Bronchodilator Agents - therapeutic use | Formoterol Fumarate - therapeutic use | Dry Powder Inhalers - economics | Glucocorticoids - therapeutic use | Humans | Administration, Inhalation | Asthma - drug therapy | Pulmonary Disease, Chronic Obstructive - epidemiology | Asthma - economics | Budesonide, Formoterol Fumarate Drug Combination - economics | Health Care Costs - trends | Sweden | Budesonide, Formoterol Fumarate Drug Combination - therapeutic use | Budesonide - therapeutic use | Adrenergic beta-2 Receptor Agonists - therapeutic use | Italy | Budesonide - administration & dosage | Dry Powder Inhalers - utilization | Pulmonary Disease, Chronic Obstructive - economics | Budesonide, Formoterol Fumarate Drug Combination - administration & dosage | Germany | Asthma - epidemiology | Formoterol Fumarate - administration & dosage | Pulmonary Disease, Chronic Obstructive - drug therapy | Health care | Corticoids | Respiratory therapy | Budesonide | Corticosteroids | Cost reduction | Disease control | Patients | Powder | Switching | Cost control | Inhalation | Health care expenditures | Formoterol | Chronic obstructive pulmonary disease | Respiration | Drug therapy | Cost engineering
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Serious Asthma Events with Budesonide plus Formoterol vs. Budesonide Alone
by Peters, Stephen P and Bleecker, Eugene R and Canonica, Giorgio W and Park, Yong B and Ramirez, Ricardo and Hollis, Sally and Fjallbrant, Harald and Jorup, Carin and Martin, Ubaldo J
The New England Journal of Medicine, ISSN 0028-4793, 09/2016, Volume 375, Issue 9, pp. 850 - 860
In adolescents and adults with moderate-to-severe asthma, the addition of formoterol to inhaled glucocorticoids was associated with a lower risk of asthma... 
MAINTENANCE | MEDICINE, GENERAL & INTERNAL | SAFETY | CLINICAL-TRIALS | DOUBLE-BLIND | INHALED CORTICOSTEROIDS | EXACERBATIONS | RELIEVER THERAPY | BUDESONIDE/FORMOTEROL | ACTING BETA-AGONISTS | SINGLE INHALER | Glucocorticoids - administration & dosage | Prospective Studies | Asthma - prevention & control | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Male | Young Adult | Adrenergic beta-2 Receptor Agonists - adverse effects | Adult | Female | Bronchodilator Agents - adverse effects | Drug Therapy, Combination | Child | Glucocorticoids - adverse effects | Double-Blind Method | Formoterol Fumarate - adverse effects | Administration, Inhalation | Asthma - drug therapy | Budesonide - adverse effects | Adolescent | Adrenergic beta-2 Receptor Agonists - administration & dosage | Aged | Budesonide - administration & dosage | Delayed-Action Preparations | Formoterol Fumarate - administration & dosage | Budesonide | Formoterol | Care and treatment | Comparative analysis | Asthma | Studies | Respiratory therapy | Adolescence | Glucocorticoids | Patient safety | Intubation | Safety | Patients
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: Pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT)
by Bateman, Eric D and Chapman, Kenneth R and Singh, Dave and D'Urzo, Anthony D and Molins, Eduard and Leselbaum, Anne and Gil, Esther Garcia
Respiratory Research, ISSN 1465-9921, 08/2015, Volume 16, Issue 1, p. 92
Background: The combination of aclidinium bromide, a long-acting anticholinergic, and formoterol fumarate, a long-acting beta2-agonist (400/12 mu g twice... 
Chronic obstructive pulmonary disease | Aclidinium bromide/formoterol fumarate | Fixed-dose combination | Symptoms | PLACEBO | EFFICACY | LUNG-FUNCTION | E-RS | PATIENT-REPORTED OUTCOMES | OBSTRUCTIVE PULMONARY-DISEASE | RESPIRATORY SYSTEM | CLINICAL-TRIALS | DOUBLE-BLIND | BROMIDE/FORMOTEROL FUMARATE | QUALITY-OF-LIFE | Pulmonary Disease, Chronic Obstructive - diagnosis | Double-Blind Method | Humans | Middle Aged | Administration, Inhalation | Male | Disease Progression | Time Factors | Anticholesteremic Agents - administration & dosage | Adrenergic beta-2 Receptor Agonists - administration & dosage | Female | Aged | Tropanes - administration & dosage | Drug Combinations | Formoterol Fumarate - administration & dosage | Pulmonary Disease, Chronic Obstructive - drug therapy | Pharmaceutical industry | Lung diseases, Obstructive | Drug therapy, Combination | Aclidinium bromide | Research | formoterol fumarate
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): A multicentre, randomised study
by Singh, Dave and Jones, Paul W and Bateman, Eric D and Korn, Stephanie and Serra, Cristina and Molins, Eduard and Caracta, Cynthia and Gil, Garcia and Leselbaum, Anne
BMC Pulmonary Medicine, ISSN 1471-2466, 11/2014, Volume 14, Issue 1, p. 178
Background: Aclidinium/formoterol is a twice-daily (BID) fixed-dose combination (FDC) in development for chronic obstructive pulmonary disease (COPD). The... 
Aclidinium bromide/formoterol fumarate | Fixed-dose combination | Chronic obstructive pulmonary disease | OBSTRUCTIVE PULMONARY-DISEASE | MANAGEMENT | RESPIRATORY SYSTEM | CLINICAL-TRIALS | EXACERBATIONS | BROMIDE | AGONISTS | BRONCHODILATORS | Severity of Illness Index | Tropanes - adverse effects | Double-Blind Method | Humans | Middle Aged | Male | Dyspnea - etiology | Pulmonary Disease, Chronic Obstructive - physiopathology | Pulmonary Disease, Chronic Obstructive - complications | Formoterol Fumarate - agonists | Forced Expiratory Volume | Vital Capacity | Quality of Life | Female | Aged | Tropanes - administration & dosage | Drug Combinations | Formoterol Fumarate - administration & dosage | Pulmonary Disease, Chronic Obstructive - drug therapy | Pharmaceutical industry | Comparative analysis | Drug therapy, Combination
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study
by Ferguson, Gary T and Tashkin, Donald P and Skärby, Tor and Jorup, Carin and Sandin, Kristina and Greenwood, Michael and Pemberton, Kristine and Trudo, Frank
Respiratory Medicine, ISSN 0954-6111, 11/2017, Volume 132, pp. 31 - 41
Prevention of exacerbations is a primary goal for chronic obstructive pulmonary disease (COPD) therapy. This randomized, double-blind, double-dummy,... 
ICS/LABA | Budesonide/formoterol | Airway | Lung | COPD | CARDIAC & CARDIOVASCULAR SYSTEMS | CLINICAL-TRIAL | EFFICACY | FLUTICASONE PROPIONATE/SALMETEROL 250/50 | BUDESONIDE | PNEUMONIA | SALMETEROL | RESPIRATORY SYSTEM | OUTCOMES | Bronchodilator Agents - therapeutic use | Glucocorticoids - administration & dosage | Glucocorticoids - therapeutic use | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Forced Expiratory Volume | Aged, 80 and over | Metered Dose Inhalers | Adult | Female | Formoterol Fumarate - therapeutic use | Severity of Illness Index | Dry Powder Inhalers | Double-Blind Method | Proportional Hazards Models | Administration, Inhalation | Treatment Outcome | Disease Progression | Vital Capacity | Budesonide, Formoterol Fumarate Drug Combination - therapeutic use | Aged | Budesonide, Formoterol Fumarate Drug Combination - administration & dosage | Formoterol Fumarate - administration & dosage | Pulmonary Disease, Chronic Obstructive - dr